LENSAR Q1 2025 Earnings Report

LENSAR EPS Results

• Actual EPS: -$2.32
• Consensus EPS: -$0.16
• Beat/Miss: Missed by -$2.17
• One Year Ago EPS: N/A

LENSAR Revenue Results

• Actual Revenue: $11.53 million
• Expected Revenue: $13.40 million
• Beat/Miss: Missed by -$1.87 million
• YoY Revenue Growth: N/A

LENSAR Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 7:00AM ET

LENSAR (NASDAQ:LNSR) is a medical technology company focused on developing and commercializing advanced laser systems for cataract surgery. The company’s flagship offering, the LENSAR Laser System, combines femtosecond laser technology with a proprietary three-dimensional imaging platform and intuitive software to enable surgeons to perform precise corneal incisions and lens fragmentation. By integrating real-time ocular measurements with automated calibration and customizable treatment protocols, LENSAR’s solution is designed to enhance surgical accuracy, reduce variability and support the use of premium intraocular lenses.

Founded in 2001 and headquartered in Orlando, Florida, LENSAR completed its initial public offering in 2016 and has since expanded its global footprint. The company’s distribution network spans North America, Latin America, Europe, the Middle East and the Asia-Pacific region, serving ophthalmology clinics and surgical centers committed to improving patient outcomes. Through partnerships with independent distributors and a growing direct sales organization, LENSAR has deployed its laser systems in leading eye care facilities and continues to pursue regulatory clearances in new markets.

Under a leadership team with deep expertise in ophthalmic devices and medical technology commercialization, LENSAR invests in ongoing research and development to advance its Unity Imaging and Software Platform. President and Chief Executive Officer David J. Dillon and Chief Medical Officer Dr. Pankaj Sharma guide the company’s strategic initiatives, which include clinical studies, product enhancements and expanded surgical applications. By focusing on innovation and surgeon collaboration, LENSAR aims to address evolving needs in cataract and refractive surgery worldwide.